Lori Leslie, MD, John Theurer Cancer Center, Hackensack University Medical Center, New Jersey, discusses results from a real-world study evaluating treatment patterns and time to next treatment in high-risk and non-high-risk patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib or chemoimmunotherapy as first-line therapy.
These results were presented at the virtual 62nd ASH Annual Meeting and Exposition.
